Linagliptine Sandoz (Linagliptin)

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher incretin levels stimulate insulin release and suppress glucagon in a glucose‑dependent manner, leading to lower blood sugar levels.

The appropriate dose of Linagliptine Sandoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin during pregnancy and lactation are limited. The drug is generally not recommended for use in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision should be made by a qualified healthcare provider.

To request Linagliptine Sandoz, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptine Sandoz is a once‑daily DPP‑4 inhibitor that does not require dose adjustment in mild to moderate renal impairment, unlike some other agents in the class. Its efficacy in lowering HbA1c is comparable to other DPP‑4 inhibitors, while its safety profile is similar, with low risk of hypoglycaemia when used as monotherapy.

Linagliptine Sandoz tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Linagliptine Sandoz is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare professional.

The most serious adverse events associated with linagliptin include pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and rare bullous skin disorders. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unusual skin eruptions.

Linagliptine Sandoz should be avoided in individuals with a known hypersensitivity to linagliptin or any of its excipients. Caution is also advised for patients with severe hepatic impairment, and it may be contraindicated in those with a history of pancreatitis or severe renal disease, pending clinical judgment.